Instil Bio reports 2022 net loss of $223M; cash runway beyond 2026; ITIL-306 phase 1 in 2H 2023

Instil Bio, Inc.

2023-Q1 EPS reported -$0.44

Cash & marketable securities $260.9M (Dec 31, 2022) vs $454.1M in 2021; cash runway beyond 2026 with <$10M quarterly burn from 2H 2023.
Net loss $223.2M in 2022 ($1.72/share) vs $156.8M ($1.48/share) in 2021; restructuring charge $23.2M.
Discontinued ITIL-168 program Dec 2022 over manufacturing issues; prioritized ITIL-306 with anticipated UK MHRA CTA clearance 2H 2023.
Initial ITIL-306 phase 1 clinical data expected in 2024; consolidated R&D ops to Manchester, UK; seeking lease/sale of Tarzana facility.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Instil Bio, Inc. reported the fourth quarter ended December 31, 2022 results: net income Net loss $ (53,844), EPS Net loss per share, basic and diluted $ (0.41).

Period: the fourth quarter ended December 31, 2022
Net income: Net loss $ (53,844)
EPS: Net loss per share, basic and diluted $ (0.41)
Result: reported results

Exact text from the filing

Net loss $ (53,844) $ (55,350) $ (223,177) $ (156,794) Net loss per share, basic and diluted $ (0.41) $ (0.43) $ (1.72) $ (1.48)

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Instil Bio, Inc. reported the full year ended December 31, 2022 results: net income Net loss $ (223,177), EPS Net loss per share, basic and diluted $ (1.72).

Period: the full year ended December 31, 2022
Net income: Net loss $ (223,177)
EPS: Net loss per share, basic and diluted $ (1.72)
Result: reported results

Exact text from the filing

Net loss $ (53,844) $ (55,350) $ (223,177) $ (156,794) Net loss per share, basic and diluted $ (0.41) $ (0.43) $ (1.72) $ (1.48)

View on SEC.gov

Browse all earnings releases →

Instil Bio, Inc. filing history →

Source: SEC EDGAR

accession 0001789769-23-000033

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.